Lumos Diagnostics, Henry Schein sign distribution deal for FebriDx Test in Iberia

Lumos Diagnostics (ASX: LDX), a leading name in rapid, point-of-care diagnostic technologies, has entered into a distribution agreement with Henry Schein Medical, S.L.U., for its FebriDx point-of-care test.

This agreement expands the distribution of the FebriDx test to Spain and Portugal, significantly broadening the test’s availability in Europe.

The FebriDx test is a quick point-of-care solution that distinguishes between viral and bacterial acute respiratory infections. It produces results within 10 minutes using blood obtained from a fingerstick. This test serves as an efficient tool for managing infectious patients across various outpatient settings, including primary care, urgent care, emergency departments, and pediatric clinics.

Henry Schein’s Medical business in Spain, part of Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions for office-based dental and medical practitioners, will oversee the sale and distribution of the FebriDx test in Spain and Portugal. Marketing and sales operations under this agreement are set to commence immediately.

Rick Corstanje, General Manager of Henry Schein Medical in Spain and Portugal, welcomed the expansion of the distribution agreement. “We are delighted to expand our distribution of FebriDx beyond the UK and into Spain and Portugal,” he said. “At Henry Schein, our goal is to help health care professionals enhance efficiencies so they can focus on delivering quality care.”

Lumos Diagnostics’ CEO, Doug Ward, expressed his enthusiasm about the growing interest in their FebriDx test and the company’s ongoing partnership with Henry Schein.

He said, “It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products. Henry Schein has been a terrific and supportive partner for Lumos in the UK, despite the headwinds the pandemic generated for products such as FebriDx. With our recent US clearance and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, and further refining our US and global sales strategy. It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the European market.”